inosine-diphosphate and Cerebrovascular-Disorders

This comparative study of the influence of cytoflavin and cardioxipin on the parameters of 24-hour arterial pressure monitoring in 56 patients with chronic cerebral circulation insufficiency, arterial hypertension and hypercholesterolemia included 32 women and 24 men aged 42-72 years divided into 3 groups matchedfor the stage of diseases, age, sex, severity of AH, total cholesterol level, and antihypertensive therapy. Patients of group 1 were treated without cytoflavin and cardioxipin. Those in group 2 received daily i/v droplet infusion of 10 mg/kg cardioxipin (20-30 droplets/min). Patients of group 3 were given daily i/v droplet infusion of 10 ml cytoflavin in 200 ml 0.9% sodium chloride solution for 10 days. 24-hour arterial pressure monitoring was used to estimate the influence of the two drugs on systolic and diastolic pressure, its daily rhythm, AP variability and frequency of elevation. The study showed that both therapeutic modalities improved daily AP rhythm as manifested in a significant increase of the number of patients with the dipper rhythm and a decrease in the number of systolic/diastolic non-dipper patients. Moreover cytoflavin significantly decreased the number of systolic over-dippers compared with control group.

Topics: Adult; Aged; Antihypertensive Agents; Arterial Pressure; Blood Pressure Monitoring, Ambulatory; Cerebrovascular Circulation; Cerebrovascular Disorders; Chronic Disease; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Flavin Mononucleotide; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Infusions, Intravenous; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Retrospective Studies; Succinates; Treatment Outcome

We studied the clinical efficacy of cytoflavin in 30 patients (group 1) with I and II stages of discirculatory encephalopathy (DE) and a depressive syndrome associated with arterial hypertension. Cytoflavin was added to standard treatment intravenously in drops in dose 10 ml per 200 ml of 0,9% NaCl during 10 days and then in dose 2 tablets twice a day during 25 days. The control group (n=29 patients) received placebo. The treatment duration was 35 days but patients were followed up for 90 days with control visits at 5, 10, 20-35 and 65-90 days of treatment. After the treatment, there was the reduction of neurological symptoms and subjective disorders in patients of group 1. The improvement of attention concentration, reasoning and speech activity as well as the gradual restoration of memory were noted at 20-35 days. The positive impact of cytoflavin on depression was dependent on its severity. The effect was higher in mild depression, also, the treatment decreased the severity of depression from "moderate" or "severe' to "mild". Cytoflavin may be recommended for patients with DE and a depressive syndrome associated with arterial hypertension as a preventive medication from the progression of cerebrovascular pathology and development of stroke.

Topics: Cerebrovascular Disorders; Depressive Disorder; Drug Combinations; Female; Flavin Mononucleotide; Humans; Hypertension; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Psychiatric Status Rating Scales; Stroke; Succinates; Treatment Outcome